TAMPA, Fla. – KeriCure, Inc., the developer of novel, safe and breathable skin and wound care products, has been accepted into Quake Capital’s New York accelerator program for Spring 2019. Quake Capital, an accelerator focused on making seed level investments in new and early stage ventures, selected KeriCure from thousands of applicants.
The Quake Capital accelerator program provides selected teams with world-class coaching, personalized mentorship targeted at each company's specific needs, and access to Quake’s extensive network of investors and strategic partners. In addition, the company receives an investment of $200,000 from Quake Capital and partner Hatcher+ – a next-generation, data-driven venture firm – as well as more than $1 million in additional incentives from partners.
“We are excited to become a part of the Quake family,” said Kerriann Greenhalgh, founder, CSO and CEO of KeriCure, Inc. “With this investment and Quake’s network of clinicians and B2B partners to help accelerate our product lines through clinical studies, private label and licensing opportunities, we are looking forward to a bright 2019 and beyond.”
Quake’s 12-week accelerator program begins on Feb. 19, and culminates with Demo Day, an exclusive event attended by Quake’s investor network and members of the entrepreneurship community. To date, participants in Quake’s past two cohorts have raised over $35 million in follow-on capital, with over 80 percent of participants successfully raising a follow-on round.
“This is an excellent opportunity for KeriCure to grow and make key relationships within Quake’s network,” said April Turley, USF’s director for technology transfer. “The value KeriCure will gain by participating in the Quake Capital Accelerator Program will help elevate the company to the next level.”
KeriCure Inc., founded in January 2011, is a USF spin-out company specializing in a highly-effective skin and wound care products that do not have the harsh chemicals and other elements seen in competitors that impede the healing process. KeriCure was formed to commercialize an advanced nanopolymer platform technology that creates natural, safe and effective skin and wound care products. KeriCure has multiple patents surrounding the platform, with part of their portfolio exclusively licensed from the University of South Florida and developed by Greenhalgh and USF Chemistry professor Dr. Edward Turos.
KeriCure’s innovative liquid bandage products have been sold through retail channels since 2013, debuting in Kroger and Publix stores in the Southeast and then expanding nationwide. The company’s range of safe, sting-free and breathable wound care products mimic the natural elastic properties of the skin while maintaining an effective germ-stopping barrier. KeriCure offers products for children, adults and animals of all kinds.
For more information about KeriCure and their products, visit Kericure.com
About the University of South Florida
The University of South Florida, established in 1956 and located in Tampa, is a high-impact global research university dedicated to student success. The USF System includes three separately accredited institutions: USF, USF St. Petersburg and USF Sarasota-Manatee. Serving more than 50,000 students, the USF System has an annual budget of $1.8 billion and an annual economic impact of $4.4 billion. USF ranks in the top 25 nationally for research expenditures among public universities, according to the National Science Foundation. In 2018, the Florida Board of Governors designated USF as a Preeminent State Research University, placing USF in the most elite category among the state’s 12 public universities. USF is a member of the American Athletic Conference.